{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:43:22Z","timestamp":1785354202025,"version":"3.55.0"},"reference-count":81,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100003074","name":"Argentinean National Agency of Scientific and Technical Research","doi-asserted-by":"publisher","award":["PICT 2017-0643"],"award-info":[{"award-number":["PICT 2017-0643"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Argentinean National Agency of Scientific and Technical Research","doi-asserted-by":"publisher","award":["PICT 2016-2056"],"award-info":[{"award-number":["PICT 2016-2056"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,3,16]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Chagas disease is an infectious tropical disease included within the group of neglected tropical\ndiseases. Though historically endemic to Latin America, it has lately spread to high-income countries\ndue to human migration. At present, there are only two available drugs, nifurtimox and benznidazole,\napproved for this treatment, both with considerable side-effects (which often result in treatment\ninterruption) and limited efficacy in the chronic stage of the disease in adults.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Drug repositioning involves finding novel therapeutic indications for known drugs, including approved,\nwithdrawn, abandoned and investigational drugs. It is today a broadly applied approach to develop\ninnovative medications, since indication shifts are built on existing safety, ADME and manufacturing\ninformation, thus greatly shortening development timeframes. Drug repositioning has been signaled as\na particularly interesting strategy to search for new therapeutic solutions for neglected and rare conditions,\nwhich traditionally present limited commercial interest and are mostly covered by the public\nsector and not-for-profit initiatives and organizations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Here, we review the applications of computer-aided technologies as systematic approaches to drug\nrepositioning in the field of Chagas disease. In silico screening represents the most explored approach,\nwhereas other rational methods such as network-based and signature-based approximations have still\nnot been applied.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666191016114839","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T15:32:54Z","timestamp":1571326374000},"page":"662-675","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["In Silico Drug Repositioning for Chagas Disease"],"prefix":"10.2174","volume":"27","author":[{"given":"Carolina L.","family":"Bellera","sequence":"first","affiliation":[{"name":"Laboratory of Bioactive Research and Development (LIDeB), Faculty of Exact Sciences, University of La Plata (UNLP), La Plata, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas N.","family":"Alberca","sequence":"additional","affiliation":[{"name":"Laboratory of Bioactive Research and Development (LIDeB), Faculty of Exact Sciences, University of La Plata (UNLP), La Plata, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L.","family":"Sbaraglini","sequence":"additional","affiliation":[{"name":"Laboratory of Bioactive Research and Development (LIDeB), Faculty of Exact Sciences, University of La Plata (UNLP), La Plata, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Talevi","sequence":"additional","affiliation":[{"name":"Laboratory of Bioactive Research and Development (LIDeB), Faculty of Exact Sciences, University of La Plata (UNLP), La Plata, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"World Health Organization Neglected tropical diseases Available at:(Accessed: July 31, 2017)","journal-title":"Neglected tropical diseases"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12410-016-9394-9","volume":"9","author":"Marinho Falc\u00e3o A.","year":"2016","unstructured":"Marinho Falc\u00e3o A.; Giorgi M.C.; Campos Vieira M.L.; Chalela W.A.; Borges-Neto S.; Chagas\u2019 disease: update on current diagnosis. Curr Cardiovasc Imaging Rep 2016,9,33","journal-title":"Curr Cardiovasc Imaging Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2017.05.001","volume":"43","author":"Antinori S.","year":"2017","unstructured":"Antinori S.; Galimberti L.; Bianco R.; Grande R.; Galli M.; Corbellino M.; Chagas disease in Europe: a review for the internist in the globalized world. Eur J Intern Med 2017,43,6-15","journal-title":"Eur J Intern Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1757913916671160","volume":"137","author":"Bello Corassa R.","year":"2017","unstructured":"Bello Corassa R.; Aceijas C.; Alves P.A.B.; Garelick H.; Evolution of Chagas\u2019 disease in Brazil. Epidemiological perspective and challenges for the future: a critical review. Perspect Public Health 2017,137(5),289-295","journal-title":"Perspect Public Health"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000030","volume":"6","author":"Moran M.","year":"2009","unstructured":"Moran M.; Guzman J.; Ropars A.L.; McDonald A.; Jameson N.; Omune B.; Ryan S.; Wu L.; Neglected disease research and development: how much are we really spending? PLoS Med 2009,6(2)","journal-title":"PLoS Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","volume":"97","author":"Rodriques Coura J.","year":"2002","unstructured":"Rodriques Coura J.; de Castro S.L.; A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002,97(1),3-24","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2174\/1568026616666160216154309","volume":"16","author":"Sbaraglini M.L.","year":"2016","unstructured":"Sbaraglini M.L.; Vanrell M.C.; Bellera C.L.; Benaim G.; Carrillo C.; Talevi A.; Romano P.S.; Neglected tropical protozoan diseases: drug repositioning as a rational option. Curr Top Med Chem 2016,16(19),2201-2222","journal-title":"Curr Top Med Chem"},{"key":"ref=8","first-page":"49","volume":"16","author":"Nalor S.","year":"2014","unstructured":"Nalor S.; Schonfeld J.M.; Therapeutic drug repurposing, repositioning and rescue - part I: overview. Drug Discov World 2014,16,49-62","journal-title":"Drug Discov World"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","volume":"57","author":"Anighoro A.","year":"2014","unstructured":"Anighoro A.; Bajorath J.; Rastelli G.; Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 2014,57(19),7874-7887","journal-title":"J Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1021\/ml300114c","volume":"3","author":"Aub\u00e9 J.","year":"2012","unstructured":"Aub\u00e9 J.; Drug repurposing and the medicinal chemist. ACS Med Chem Lett 2012,3(6),442-444","journal-title":"ACS Med Chem Lett"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","volume":"19","author":"Jin G.","year":"2014","unstructured":"Jin G.; Wong S.T.C.; Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014,19(5),637-644","journal-title":"Drug Discov Today"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2174\/15680266113136660164","volume":"13","author":"Bolg\u00e1r B.","year":"2013","unstructured":"Bolg\u00e1r B.; Arany \u00c1.; Temesi G.; Balogh B.; Antal P.; M\u00e1tyus P.; Drug repositioning for treatment of movement disorders: from serendipity to rational discovery strategies. Curr Top Med Chem 2013,13(18),2337-2363","journal-title":"Curr Top Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/138955751503150312120208","volume":"15","author":"Bellera C.L.","year":"2015","unstructured":"Bellera C.L.; Sbaraglini M.L.; Balcazar D.E.; Fraccaroli L.; Vanrell M.C.; Casassa A.F.; Labriola C.A.; Romano P.S.; Carrillo C.; Talevi A.; High-throughput drug repositioning for the discovery of new treatments for Chagas disease. Mini Rev Med Chem 2015,15(3),182-193","journal-title":"Mini Rev Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nbt0712-571a","volume":"30","author":"Allison M.","year":"2012","unstructured":"Allison M.; NCATS launches drug repurposing program. Nat Biotechnol 2012,30(7),571-572","journal-title":"Nat Biotechnol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm0911-1027","volume":"17","author":"Dolgin E.","year":"2011","unstructured":"Dolgin E.; Nonprofit disease groups earmark grants for drug repositioning. Nat Med 2011,17(9),1027","journal-title":"Nat Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"Wishart D.S.","year":"2008","unstructured":"Wishart D.S.; Knox C.; Guo A.C.; Cheng D.; Shrivastava S.; Tzur D.; Gautam B.; Hassanali M.; DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008,36(Database issue),D901-D906","journal-title":"Nucleic Acids Res"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079568","volume":"8","author":"Novick P.A.","year":"2013","unstructured":"Novick P.A.; Ortiz O.F.; Poelman J.; Abdulhay A.Y.; Pande V.S.; \n                        SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery. PLoS One 2013,8(11)","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.29","volume":"4","author":"Brown A.S.","year":"2017","unstructured":"Brown A.S.; Patel C.J.; A standard database for drug repositioning. Sci Data 2017,4","journal-title":"Sci Data"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038%2Fnm.4306","volume":"23","author":"Corsello S.M.","year":"2017","unstructured":"Corsello S.M.; Bittker J.A.; Liu Z.; Gould J.; McCarren P.; Hirschman J.E.; Johnston S.E.; Vrcic A.; Wong B.; Khan M.; Aiedu J.; Narayan R.; Mader C.C.; Subramanian A.; Golub T.R.; The drug repurposing hub: a next generation drug library and information resource. Nat Med 2017,23,105-408","journal-title":"Nat Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1016\/j.bmcl.2016.03.103","volume":"26","author":"Klug D.M.","year":"2016","unstructured":"Klug D.M.; Gelb M.H.; Pollastri M.P.; Repurposing strategies for tropical disease drug discovery. Bioorg Med Chem Lett 2016,26(11),2569-2576","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.drudis.2016.06.021","volume":"21","author":"Ferreira L.G.","year":"2016","unstructured":"Ferreira L.G.; Andricopulo A.D.; Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. Drug Discov Today 2016,21(10),1699-1710","journal-title":"Drug Discov Today"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2174\/1568026618666180509151146","volume":"18","author":"Bellera C.L.","year":"2018","unstructured":"Bellera C.L.; Sbaraglini M.L.; Talevi A.; Modern approaches for the discovery of anti-infectious drugs for the treatment of neglected diseases. Curr Top Med Chem 2018,18(5),369-381","journal-title":"Curr Top Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","volume":"16","author":"Ekins S.","year":"2011","unstructured":"Ekins S.; Williams A.J.; Krasowski M.D.; Freundlich J.S.; \n                        In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 2011,16(7-8),298-310","journal-title":"Drug Discov Today"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/bib\/bbr021","volume":"12","author":"Sardana D.","year":"2011","unstructured":"Sardana D.; Zhu C.; Zhang M.; Gudivada R.C.; Yang L.; Jegga A.G.; Drug repositioning for orphan diseases. Brief Bioinform 2011,12(4),346-356","journal-title":"Brief Bioinform"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.drudis.2017.10.009","volume":"23","author":"Delavan B.","year":"2018","unstructured":"Delavan B.; Roberts R.; Huang R.; Bao W.; Tong W.; Liu Z.; Computational drug repositioning for rare diseases in the era of precision medicine. Drug Discov Today 2018,23(2),382-394","journal-title":"Drug Discov Today"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/gm326","volume":"4","author":"Li Y.Y.","year":"2012","unstructured":"Li Y.Y.; Jones S.J.I.; Drug repositioning for personalized medicine. Genome Med 2012,4(3),27","journal-title":"Genome Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1128\/AAC.00680-13","volume":"57","author":"Siles S.A.","year":"2013","unstructured":"Siles S.A.; Srinivasan A.; Pierce C.G.; L\u00f3pez-Ribot J.L.; Ramasubramanian A.K.; High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother 2013,57(8),3681-3687","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2017.04.001","volume":"23","author":"Ciallella J.R.","year":"2017","unstructured":"Ciallella J.R.; Reaume A.G.; \n                        In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach. Drug Discov Today Technol 2017,23,45-52","journal-title":"Drug Discov Today Technol"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135556","volume":"10","author":"Kaiser M.","year":"2015","unstructured":"Kaiser M.; M\u00e4ser P.; Tadoori L.P.; Ioset J.R.; Brun R.; Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning. PLoS One 2015,10(8)","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/9780470559277.ch110252","volume":"4","author":"Dandapani S.","year":"2012","unstructured":"Dandapani S.; Rosse G.; Southall N.; Salvino J.M.; Thomas C.J.; Salvino J.M.; Thomas C.J.; Selecting, acquiring, and using small molecule libraries for high-throughput screening. Curr Protoc Chem Biol 2012,4,177-191","journal-title":"Curr Protoc Chem Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2174\/138620711795767802","volume":"14","author":"Harris C.J.","year":"2011","unstructured":"Harris C.J.; Hill R.D.; Sheppard D.W.; Slater M.J.; Stouten P.F.W.; The design and application of target-focused compound libraries. Comb Chem High Throughput Screen 2011,14(6),521-531","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=32","author":"Bellera C.L.","year":"2014","unstructured":"Bellera C.L.; Di Ianni M.E.; Sbaraglini M.L.; Castro E.A.; Bruno-Blanch L.E.; Talevi A.;  Frontiers in computational chemistry 2014","journal-title":"Frontiers in computational chemistry"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1021\/ci400155x","volume":"53","author":"Wu L.","year":"2013","unstructured":"Wu L.; Ai N.; Liu Y.; Wang Y.; Fan X.; Relating anatomical therapeutic indications by the ensemble similarity of drug sets. J Chem Inf Model 2013,53(8),2154-2160","journal-title":"J Chem Inf Model"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nbt1284","volume":"25","author":"Keiser M.J.","year":"2007","unstructured":"Keiser M.J.; Roth B.L.; Armbruster B.N.; Ernsberger P.; Irwin J.J.; Shoichet B.K.; Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007,25(2),197-206","journal-title":"Nat Biotechnol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","volume":"462","author":"Keiser M.J.","year":"2009","unstructured":"Keiser M.J.; Setola V.; Irwin J.J.; Laggner C.; Abbas A.I.; Hufeisen S.J.; Jensen N.H.; Kuijer M.B.; Matos R.C.; Tran T.B.; Whaley R.; Glennon R.A.; Hert J.; Thomas K.L.; Edwards D.D.; Shoichet B.K.; Roth B.L.; Predicting new molecular targets for known drugs. Nature 2009,462(7270),175-181","journal-title":"Nature"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065894","volume":"8","author":"Haupt V.J.","year":"2016","unstructured":"Haupt V.J.; Daminelli S.; Schroeder M.; Drug promiscuity in PDB: protein binding site similarity is key. PLoS One 2016,8(6)","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1021\/acs.jmedchem.6b00078","volume":"59","author":"Ehrt C.","year":"2016","unstructured":"Ehrt C.; Brinkjost T.; Koch O.; Impact of binding site comparisons on medicinal chemistry and rational molecular design. J Med Chem 2016,59(9),4121-4151","journal-title":"J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/bib\/bbr011","volume":"12","author":"Haupt V.J.","year":"2011","unstructured":"Haupt V.J.; Schroeder M.; Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform 2011,12(4),312-326","journal-title":"Brief Bioinform"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.pbiomolbio.2014.05.006","volume":"116","author":"Salentin S.","year":"2014","unstructured":"Salentin S.; Haupt V.J.; Daminelli S.; Schroeder M.; Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity assessment. Prog Biophys Mol Biol 2014,116(2-3),174-186","journal-title":"Prog Biophys Mol Biol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1021\/acschembio.5b00683","volume":"10","author":"Barelier S.","year":"2015","unstructured":"Barelier S.; Sterling T.; O\u2019Meara M.J.; Shoichet B.K.; The recognition of identical ligands by unrelated proteins. ACS Chem Biol 2015,10(12),2772-2784","journal-title":"ACS Chem Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jbi.2012.07.003","volume":"45","author":"Cohen T.","year":"2012","unstructured":"Cohen T.; Widdows D.; Schvaneveldt R.W.; Davies P.; Rindflesch T.C.; Discovering discovery patterns with predication-based semantic indexing. J Biomed Inform 2012,45(6),1049-1065","journal-title":"J Biomed Inform"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrg1768","volume":"7","author":"Jensen L.J.","year":"2006","unstructured":"Jensen L.J.; Saric J.; Bork P.; Literature mining for the biologist: from information retrieval to biological discovery. Nat Rev Genet 2006,7(2),119-129","journal-title":"Nat Rev Genet"},{"key":"ref=43","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.3154","volume":"5","author":"Su E.W.","year":"2017","unstructured":"Su E.W.; Sanger T.M.; Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov. PeerJ 2017,5","journal-title":"PeerJ"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.cell.2011.02.016","volume":"144","author":"Vidal M.","year":"2011","unstructured":"Vidal M.; Cusick M.E.; Barab\u00e1si A.L.; Interactome networks and human disease. Cell 2011,144(6),986-998","journal-title":"Cell"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002574","volume":"8","author":"Chen B.","year":"2012","unstructured":"Chen B.; Ding Y.; Wild D.J.; Assessing drug target association using semantic linked data. PLOS Comput Biol 2012,8(7)","journal-title":"PLOS Comput Biol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1758-2946-4-6","volume":"4","author":"Chen B.","year":"2012","unstructured":"Chen B.; Ding Y.; Wild D.J.; Improving integrative searching of systems chemical biology data using semantic annotation. J Cheminform 2012,4(1),6","journal-title":"J Cheminform"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fphar.2015.00205","volume":"6","author":"Talevi A.","year":"2015","unstructured":"Talevi A.; Multi-target pharmacology: possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective. Front Pharmacol 2015,6,205","journal-title":"Front Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"Pi\u00f1ero J.","year":"2017","unstructured":"Pi\u00f1ero J.; Bravo \u00c0.; Queralt-Rosinach N.; Guti\u00e9rrez-Sacrist\u00e1n A.; Deu-Pons J.; Centeno E.; Garc\u00eda-Garc\u00eda J.; Sanz F.; Furlong L.I.; DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res 2017,45(D1),D833-D839","journal-title":"Nucleic Acids Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"D1069","DOI":"10.1093\/nar\/gkv1230","volume":"44","author":"Yang H.","year":"2016","unstructured":"Yang H.; Qin C.; Li Y.H.; Tao L.; Zhou J.; Yu C.Y.; Xu F.; Chen Z.; Zhu F.; Chen Y.Z.; Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res 2016,44(D1),D1069-D1074","journal-title":"Nucleic Acids Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"Szklarczyk D.","year":"2015","unstructured":"Szklarczyk D.; Franceschini A.; Wyder S.; Forslund K.; Heller D.; Huerta-Cepas J.; Simonovic M.; Roth A.; Santos A.; Tsafou K.P.; Kuhn M.; Bork P.; Jensen L.J.; von Mering C.; STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015,43(Database issue),D447-D452","journal-title":"Nucleic Acids Res"},{"key":"ref=51","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv1072","volume":"44","author":"Gilson M.K.","year":"2016","unstructured":"Gilson M.K.; Liu T.; Baitaluk M.; Nicola G.; Hwang L.; Chong J.; BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 2016,44(D1)","journal-title":"Nucleic Acids Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.drudis.2012.07.014","volume":"18","author":"Iorio F.","year":"2013","unstructured":"Iorio F.; Rittman T.; Ge H.; Menden M.; Saez-Rodr\u00edguez J.; Transcriptional data: a new gateway to drug repositioning? Drug Discov Today 2013,18(7-8),350-357","journal-title":"Drug Discov Today"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006536","volume":"4","author":"Hu G.","year":"2009","unstructured":"Hu G.; Agarwal P.; Human disease-drug network based on genomic expression profiles. PLoS One 2009,4(8)","journal-title":"PLoS One"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002347","volume":"8","author":"Shigemizu D.","year":"2012","unstructured":"Shigemizu D.; Hu Z.; Hung J.H.; Huang C.L.; Wang Y.; DeLisi C.; Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLOS Comput Biol 2012,8(2)","journal-title":"PLOS Comput Biol"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177743","volume":"12","author":"Wu H.","year":"2017","unstructured":"Wu H.; Huang J.; Zhong Y.; Huang Q.; DrugSig: a resource for computational drug repositioning utilizing gene expression signatures. PLoS One 2017,12(5)","journal-title":"PLoS One"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"Lamb J.","year":"2006","unstructured":"Lamb J.; Crawford E.D.; Peck D.; Modell J.W.; Blat I.C.; Wrobel M.J.; Lerner J.; Brunet J.P.; Subramanian A.; Ross K.N.; Reich M.; Hieronymus H.; Wei G.; Armstrong S.A.; Haggarty S.J.; Clemons P.A.; Wei R.; Carr S.A.; Lander E.S.; Golub T.R.; The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006,313(5795),1929-1935","journal-title":"Science"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.2174\/1568026616666160927160912","volume":"17","author":"Sbaraglini M.L.","year":"2017","unstructured":"Sbaraglini M.L.; Talevi A.; Hybrid compounds as antiinfective agents. Curr Top Med Chem 2017,17(9),1080-1095","journal-title":"Curr Top Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/jcb.25978","volume":"118","author":"Garc\u00eda-Huertas P.","year":"2017","unstructured":"Garc\u00eda-Huertas P.; Mej\u00eda-Jaramillo A.M.; Gonz\u00e1lez L.; Triana-Ch\u00e1vez O.; Transcriptome and functional genomics reveal the participation of adenine phosphoribosyltransferase in Trypanosoma cruzi resistance to benznidazole. J Cell Biochem 2017,118(7),1936-1945","journal-title":"J Cell Biochem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.actatropica.2012.01.001","volume":"122","author":"Soares M.B.P.","year":"2012","unstructured":"Soares M.B.P.; Silva C.V.; Bastos T.M.; Guimar\u00e3es E.T.; Figueira C.P.; Smirlis D.; Azevedo W.F.; Anti-Trypanosoma cruzi activity of nicotinamide. Acta Trop 2012,122(2),224-229","journal-title":"Acta Trop"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1021\/ci400284v","volume":"53","author":"Bellera C.L.","year":"2013","unstructured":"Bellera C.L.; Balcazar D.E.; Alberca L.; Labriola C.A.; Talevi A.; Carrillo C.; Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery of amiodarone and bromocriptine inhibitory effects. J Chem Inf Model 2013,53(9),2402-2408","journal-title":"J Chem Inf Model"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/279618","volume":"2014","author":"Bellera C.L.","year":"2014","unstructured":"Bellera C.L.; Balcazar D.E.; Alberca L.; Labriola C.A.; Talevi A.; Carrillo C.; Identification of levothyroxine antichagasic activity through computer-aided drug repurposing. ScientificWorldJournal 2014,2014","journal-title":"ScientificWorldJournal"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ejmech.2015.01.065","volume":"93","author":"Bellera C.L.","year":"2015","unstructured":"Bellera C.L.; Balcazar D.E.; Vanrell M.C.; Casassa A.F.; Palestro P.H.; Gavernet L.; Labriola C.A.; G\u00e1lvez J.; Bruno-Blanch L.E.; Romano P.S.; Carrillo C.; Talevi A.; Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. Eur J Med Chem 2015,93,338-348","journal-title":"Eur J Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF00618517","volume":"15","author":"Friis M.L.","year":"1979","unstructured":"Friis M.L.; Gr\u00f8n U.; Larsen N.E.; Pakkenberg H.; Hvidberg E.F.; Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson\u2019s disease. Eur J Clin Pharmacol 1979,15(4),275-280","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/BF00635902","volume":"29","author":"del Pozo E.","year":"1986","unstructured":"del Pozo E.; Schl\u00fcter K.; N\u00fcesch E.; Rosenthaler J.; Kerp L.; Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. Eur J Clin Pharmacol 1986,29(5),615-618","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/adt.2015.29011.tiodrrr","volume":"13","author":"Oprea T.I.","year":"2015","unstructured":"Oprea T.I.; Overington J.P.; Computational and practical aspects of drug repositioning. Assay Drug Dev Technol 2015,13(6),299-306","journal-title":"Assay Drug Dev Technol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","volume":"15","author":"Field M.C.","year":"2017","unstructured":"Field M.C.; Horn D.; Fairlamb A.H.; Ferguson M.A.J.; Gray D.W.; Read K.D.; De Rycker M.; Torrie L.S.; Wyatt P.G.; Wyllie S.; Gilbert I.H.; Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol 2017,15(4),217-231","journal-title":"Nat Rev Microbiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijantimicag.2016.02.018","volume":"48","author":"Sbaraglini M.L.","year":"2016","unstructured":"Sbaraglini M.L.; Bellera C.L.; Fraccaroli L.; Larocca L.; Carrillo C.; Talevi A.; Alba Soto C.D.; Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. Int J Antimicrob Agents 2016,48(1),91-95","journal-title":"Int J Antimicrob Agents"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/molecules22061015","volume":"22","author":"Palos I.","year":"2017","unstructured":"Palos I.; Lara-Ramirez E.E.; Lopez-Cedillo J.C.; Garcia-Perez C.; Kashif M.; Bocanegra-Garcia V.; Nogueda-Torres B.; Rivera G.; \n                        GarciaPerez, C.; Kashif, M.; Bocanegra-Garcia, V.; NoguedaTorres, B.; Rivera, G. Repositioning FDA drugs as potential cruzain inhibitors from Trypanosoma cruzi: virtual screening, in vitro and in vivo studies. Molecules 2017,22(6),1015","journal-title":"Molecules"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10822-016-9903-6","volume":"30","author":"Alberca L.N.","year":"2016","unstructured":"Alberca L.N.; Sbaraglini M.L.; Balcazar D.; Fraccaroli L.; Carrillo C.; Medeiros A.; Ben\u00edtez D.; Comini M.; Talevi A.; Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning. J Comput Aided Mol Des 2016,30(4),305-321","journal-title":"J Comput Aided Mol Des"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00003088-199324030-00003","volume":"24","author":"van Harten J.","year":"1993","unstructured":"van Harten J.; Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993,24(3),203-220","journal-title":"Clin Pharmacokinet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1177\/1087057115569155","volume":"20","author":"Kaiser M.","year":"2015","unstructured":"Kaiser M.; Maes L.; Tadoori L.P.; Spangenberg T.; Ioset J.R.P.; Spangenber T.; Joset J.R.; Repurposing of the open access malaria box for kinetoplastid diseases identifies novel active scaffolds against trypanosomatids. J Biomol Screen 2015,20(5),634-645","journal-title":"J Biomol Screen"},{"key":"ref=72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005472","volume":"11","author":"Reigada C.","year":"2017","unstructured":"Reigada C.; Valera-Vera E.A.; Say\u00e9 M.; Errasti A.E.; Avila C.C.; Miranda M.R.; Pereira C.A.; Trypanocidal effect of isotretinoin through the inhibition of polyamine and amino acid transporters in Trypanosoma cruzi. PLoS Negl Trop Dis 2017,11(3)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/BF00542224","volume":"24","author":"Colburn W.A.","year":"1983","unstructured":"Colburn W.A.; Vane F.M.; Shorter H.J.; Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. Eur J Clin Pharmacol 1983,24(5),689-694","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ejmech.2017.03.063","volume":"132","author":"Lara-Ramirez E.E.","year":"2017","unstructured":"Lara-Ramirez E.E.; L\u00f3pez-Cedillo J.C.; Nogueda-Torres B.; Kashif M.; Garcia-Perez C.; Bocanegra-Garcia V.; Agusti R.; Uhrig M.L.; Rivera G.; An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. Eur J Med Chem 2017,132,249-261","journal-title":"Eur J Med Chem"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.21664\/2238-8869.2015v4i1.p77-84","volume":"4","author":"Rodrigues J.","year":"2015","unstructured":"Rodrigues J.; Alves N.R.; Da Silva F.G.; Cravo P.V.L.; Identification of new drugs against chagas disease through genomics and bioinformatics strategies. Fronteiras 2015,4,77-84","journal-title":"Fronteiras"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1210\/jcem.79.2.8045964","volume":"79","author":"Fl\u00f8gstad A.K.","year":"1994","unstructured":"Fl\u00f8gstad A.K.; Halse J.; Grass P.; Abisch E.; Dj\u00f8seland O.; Kutz K.; Bodd E.; Jervell J.; A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994,79(2),461-465","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003495-199652010-00007","volume":"52","author":"Noble S.","year":"1996","unstructured":"Noble S.; Faulds D.; Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996,52(1),93-112","journal-title":"Drugs"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkr444","volume":"67","author":"Cholo M.C.","year":"2012","unstructured":"Cholo M.C.; Steel H.C.; Fourie P.B.; Germishuizen W.A.; Anderson R.; Clofazimine: current status and future prospects. J Antimicrob Chemother 2012,67(2),290-298","journal-title":"J Antimicrob Chemother"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1600-0447.1989.tb07176.x","volume":"350","author":"Kaye C.M.","year":"1989","unstructured":"Kaye C.M.; Haddock R.E.; Langley P.F.; Mellows G.; Tasker T.C.G.; Zussman B.D.; Greb W.H.; A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989,350,60-75","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/j.1552-4604.1998.tb04388.x","volume":"38","author":"Nulman I.","year":"1998","unstructured":"Nulman I.; Berkovitch M.; Klein J.; Pastuszak A.; Lester R.S.; Shear N.; Koren G.; Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 1998,38(10),926-930","journal-title":"J Clin Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","volume":"10","author":"Klotz U.","year":"1985","unstructured":"Klotz U.; Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985,10(4),285-302","journal-title":"Clin Pharmacokinet"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T11:23:20Z","timestamp":1585394600000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175745\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666191016114839","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}